CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success?
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Nassif, Najah Therese
Simpson, Ann Margaret
Funding for this research was provided by:
University of Technology Sydney